Principal Scientist Regeneron Pharmaceuticals Tarrytown, New York, United States
This talk will cover background of a virus-like particle (VLP) containing an innate immune response agonist. It will also go over ADA assay development of an electrochemiluminescent assay, including challenges in reagent conjugation, and bioanalytical strategy for a VLP drug.
Learning Objectives:
Describe challenges associated with developing an ADA assay for a virus-like particle therapeutic
Debate the significance of anti-drug antibody data for a therapeutic expecting high titers in all patients
Extrapolate challenges and considerations from one VLP-based drug and apply them to other new and emerging therapeutics
